BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of ...

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $269 from $265 and keeps a Buy rating ...

BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

In keeping with the trend in med tech to return to basics, Becton, Dickinson and Co. plans to split off its biosciences and diagnostic solutions unit to create two pure-play companies. The ‘New BD’ or ...

Empowering medical professionals with the latest imaging technologies in early screening, detection, and diagnostics ...

SG Americas Securities LLC cut its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) by 28.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 12,518 shares of the company ...